title: Clinical binding properties, internalization kinetics, and clinicopathologic activity of brentuximab vedotin: an antibody-drug conjugate for CD30-positive lymphoid neoplasms.
authors.affiliation: Department of Laboratory Medicine, University of Washington, Seattle, Washington 98195, USA. jfromm@u.washington.edu
authors.forename: Jonathan R
authors.initials: JR
authors.lastname: Fromm
authors.forename: Julie A
authors.initials: JA
authors.lastname: McEarchern
authors.forename: Dana
authors.initials: D
authors.lastname: Kennedy
authors.forename: Anju
authors.initials: A
authors.lastname: Thomas
authors.forename: Andrei R
authors.initials: AR
authors.lastname: Shustov
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D000079963:Brentuximab Vedotin; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D017730:Ki-1 Antigen / Q000378:metabolism*; D017728:Lymphoma, Large-Cell, Anaplastic / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin